The Chamber of Commerce’s lawsuit is the first test of a barrage of lawsuits from the pharmaceutical industry and its allies over the new law.
A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday over whether drugmakers have enough say in Medicare’s new drug price negotiation program, in ...
The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
The decision preserves the Biden administration’s power to begin haggling with drug companies over the prices of 10 medications.
PhRMA, a leading drug industry trade group, and the US Chamber of Commerce have also filed suits. More on Medicare drug pricing: Medicare lists first ten drugs selected for pricing negotiations ...
The U.S. government's Medicare health insurance program can begin negotiating prices for some prescription drugs this fall under a new program, a federal judge ruled on Friday, vindicating one of ...
As we have covered in previous articles here, the new authority Congress provided to the Department of Health and Human Services (HHS) under the Inflation Reduction Act (IRA) to directly negotiate ...
The Ohio Chamber of Commerce has come out in opposition to Issue 2 out of concerns for the ramifications recreational marijuana might have on employers and their workforces. But whether those concerns ...
The Master of Science degree program in Drug Discovery & Development (DDD) offers students the opportunity to understand, evaluate and engage with the entire process of drug discovery and development.
Sept 15 (Reuters) - A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
